MARKET

GLYC

GLYC

GlycoMimetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.060
-0.220
-9.65%
Closed 16:05 04/01 EDT
OPEN
2.220
PREV CLOSE
2.280
HIGH
2.260
LOW
2.050
VOLUME
261.06K
TURNOVER
--
52 WEEK HIGH
13.44
52 WEEK LOW
1.820
MARKET CAP
89.78M
P/E (TTM)
-1.5390
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GLYC stock price target is 8.80 with a high estimate of 16.00 and a low estimate of 4.000.

EPS

GLYC News

More
  • Edited Transcript of GLYC earnings conference call or presentation 28-Feb-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/25 02:19
  • Daniel Junius Is The Independent Director of GlycoMimetics, Inc. (NASDAQ:GLYC) And They Just Spent US$68k On Shares
  • Simply Wall St. · 03/11 12:36
  • GlycoMimetics Inc (GLYC) Q4 2019 Earnings Call Transcript
  • MotleyFool.com · 03/04 22:33
  • H.C. Wainwright Reiterates Buy on GlycoMimetics, Lowers Price Target to $16
  • Benzinga · 03/02 12:28

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About GLYC

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
More

Webull offers kinds of GlycoMimetics Inc stock information, including NASDAQ:GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions.